A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

NCT02613208 · clinicaltrials.gov ↗

COMPLETED

Status

111

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Bevacizumab
DRUG: Paclitaxel

Sponsor

Hoffmann-La Roche